Profoundbio Announces Completion Of More Than $55 Million Series A Financing To Advance Novel Antibody-Drug Conjugate (Adc) Portfolio
Profoundbio Announces Completion Of More Than $55 Million Series A Financing To Advance Novel Antibody-Drug Conjugate (Adc) Portfolio
07/12/21, 9:02 AM
Location
woodinvilleMoney raised
$55 million
Round Type
series a
ProfoundBio announced the closing of a $55+ million Series A financing round led by Lilly Asia Venture and co-led by LYFE Capital, with participation from Sequoia Capital China and Oriza. All investors from the Series Pre-A financing, K2VC, Gaorong Capital, and Chang'an Capital, also participated in this round of financing.
Company Info
Location
woodinville, washington, united states
Additional Info
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on innovative technology platforms, ProfoundBio has developed a pipeline consisting of multiple solid tumor-targeting drug candidates that are currently in discovery and preclinical development stages. ProfoundBio has operations in both the greater Seattle area, WA, USA and Suzhou, China.
For more information, please visit www.profoundbio.com.